^
    3d
    OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Oncolytic virus • Metastases
    |
    BS001
    3d
    OH2 Injection in Solid Tumors (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • BS001
    3d
    OH2 Oncolytic Viral Therapy in Solid Tumors (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    irinotecan • Puyouheng (pucotenlimab) • BS001
    3d
    OH2 Administered by Intratumoral Injection (clinicaltrials.gov)
    P1, N=29, Not yet recruiting, Binhui Biopharmaceutical Co., Ltd. | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jul 2025 --> Jul 2027
    Trial completion date • Trial primary completion date • Oncolytic virus • Metastases
    |
    BS001
    5d
    Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=14, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim) • octreotide acetate
    5d
    Adjuvant Radiation Therapy in Macroscopic Regional Nodal Melanoma. (PubMed, Cancers (Basel))
    After the advent of systemic therapies, a trial of the combination targeted therapy of dabrafenib plus trametinib toward BRAF V600-mutant nodal cutaneous melanoma showed that all 35 patients achieved a pathological response...For those tumours that do recur in-field, there are now competing therapies like Talimogene laherparepvec or T-VEC. Generally, ART is now used at the first recurrence. The challenge now is to find which melanomas are truly radiosensitive if ART is to have any future role in this scenario.
    Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • NODAL (Nodal Growth Differentiation Factor)
    |
    BRAF V600E • BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Imlygic (talimogene laherparepvec)
    13d
    Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
    P1/2, N=46, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Completed | N=30 --> 46 | Trial completion date: Dec 2024 --> Sep 2024 | Trial primary completion date: Dec 2024 --> Sep 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
    24d
    Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure (clinicaltrials.gov)
    P2, N=56, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Active, not recruiting | N=162 --> 56
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • pentostatin • Neupogen (filgrastim)
    26d
    GPAD-3: Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (clinicaltrials.gov)
    P2, N=176, Recruiting, Emory University | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Leukine (sargramostim)
    1m
    Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=10, Completed, Karie D. Runcie, MD | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    Imlygic (talimogene laherparepvec)
    1m
    Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung (clinicaltrials.gov)
    P1, N=20, Suspended, Mayo Clinic | Trial completion date: Oct 2024 --> Jan 2026 | Withdrawn --> Suspended | Trial primary completion date: Oct 2024 --> Jan 2026
    Trial completion date • Trial suspension • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Leukine (sargramostim)
    1m
    G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Massachusetts General Hospital | N=40 --> 60
    Enrollment change
    |
    temozolomide • Neupogen (filgrastim)
    1m
    TEMPO: Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (clinicaltrials.gov)
    P1, N=28, Completed, Dan Blazer III, M.D. | N=19 --> 28
    Enrollment change
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Imlygic (talimogene laherparepvec)
    1m
    Phase I Study of Adjuvant Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine, Low Dose Cyclophosphamide, and SBRT followed by FFX in High-Risk Resected Pancreatic Ductal Adenocarcinoma. (PubMed, Int J Radiat Oncol Biol Phys)
    This is the first prospective trial to evaluate adjuvant GVAX, Cy, SBRT, and mFFX in resected PDAC patients with high-risk features. This combination regimen was well tolerated with limited toxicity and promising survival outcomes, warranting future studies to validate this regimen in the adjuvant setting.
    P1 data • Journal • Tumor cell
    |
    CSF2 (Colony stimulating factor 2)
    |
    5-fluorouracil • cyclophosphamide • irinotecan • leucovorin calcium • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
    1m
    Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer. (PubMed, Gynecol Oncol)
    RADD revealed DNA repair proficiency without mutation signatures or expression profiling. High DNA damage levels show improved survival for Vigil maintenance therapies and are correlated with immune evasion proteins. The persistence of DNA lesions in the genomic DNA offers a new biomarker for immunotherapy patient stratification.
    Journal • IO biomarker
    |
    ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    ENTPD1 expression
    |
    Vigil (gemogenovatucel-T)
    1m
    G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Massachusetts General Hospital | N=60 --> 40
    Enrollment change
    |
    temozolomide • Neupogen (filgrastim)
    1m
    Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • IO biomarker • Surgery
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Imlygic (talimogene laherparepvec)
    1m
    Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=24 --> 0 | Trial completion date: Dec 2029 --> Nov 2024 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2029 --> Nov 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    paclitaxel • Neupogen (filgrastim)
    2ms
    Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease (clinicaltrials.gov)
    P1, N=11, Completed, University of Nebraska | Active, not recruiting --> Completed
    Trial completion
    |
    Leukine (sargramostim)
    2ms
    NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (clinicaltrials.gov)
    P2, N=62, Recruiting, New Approaches to Neuroblastoma Therapy Consortium | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    temozolomide • irinotecan • Unituxin (dinutuximab) • Leukine (sargramostim)
    2ms
    Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients with Metastatic Melanoma to the Lung (clinicaltrials.gov)
    P1, N=0, Withdrawn, Mayo Clinic | N=24 --> 0 | Trial completion date: Jul 2025 --> Oct 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2025 --> Oct 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Leukine (sargramostim)
    2ms
    Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov)
    P2, N=54, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2024 --> Dec 2024
    Trial completion date
    |
    lenalidomide • allogeneic Myeloma GM-CSF Vaccine
    2ms
    Neoadjuvant Intralesional Injection of Talimogene Laherparepvec (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, John Rieth
    New P1 trial • Metastases
    |
    Imlygic (talimogene laherparepvec)
    2ms
    Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma (clinicaltrials.gov)
    P3, N=479, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Dec 2025
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • mesna • Neupogen (filgrastim)
    2ms
    MP-11: Moderated Oral ePoster Session: Kidney and Ureteral Cancer - Clinical (SIU 2024)
    MP-10.01 Diffusion-Weighted Magnetic Resonance Imaging for Assessment of Tumor Response in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Prospective StudyAbbas Basiri, Iran, Islamic Rep. MP-10.02 Divergent Experiences of Bladder Cancer Patients: A Focus on Advanced and Metastatic Disease StagesAlex Filicevas, Belgium MP-10.03 Evolution of a Rapid, Simple Urine Test for Detecting Volatile Organic Compound (VOC) in Urine by a High Performance Portable Device (NABIL) for Detection of Urinary Bladder CarcinomaSaurav Karmakar, India MP-10.04 Intraoperative ICG Fluorescence as a Method of Prevention of Postoperative Strictures of Uretero-Ileoanastomoses During Robot-Assisted Radical CystectomyValentin Pavlov, Russian Federation MP-10.05 Intravesical Gemcitabine and Docetaxel in Patients with High Risk NMIBC: Our ExperienceDeepak Krishnappa, India MP-10.06 On Block Robot-Assisted Radical Cystectomy: New Method for Bladder CancerValentin Pavlov, Russian Federation MP-10.07 Oncological Outcomes with the 80mg Dose of the Moscow Strain of Intravesical BCG for Non-Muscle Invasive Bladder Cancer: Implications for Global ShortageAmandeep Arora, India MP-10.08 Outcome of Robot-Assisted Radical Cystectomy with Intracorporeal Creation of Heterotopic NeocystisValentin Pavlov, Russian Federation MP-10.09 Proposed Novel Surveillance Schedule Using Cx Monitor for Patients on Annual Bladder Cancer SurveillanceArjun Guduguntla, Australia MP-10.10 Quality of Primary TURBTs for Non-Muscle Invasive Bladder Cancer PatientsSaurabh Verma, United Kingdom MP-10.11 TAR-200 in Patients with Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results from the SunRISe-1 StudyAndrea Necchi, United States MP-10.12 Timeline Analysis of Muscle Invasive Bladder Cancer PatientsSaurabh Verma, United Kingdom MP-10.13 Transurethral Resection of Bladder Tumour (TURBT) Operative Notes: How to Improve Their QualitySaurabh Verma, United Kingdom MP-10.14 Trial in Progress: PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder TumorRobert Svatek, United States MP-10.15 URO17® Urine Test For Bladder Cancer - Meta AnalysisNikhil Vasdev, United Kingdom MP-10.16 Usefulness of UF-5000 Automatic Screening System in Urothelial Carcinoma DiagnosisTadahiko Kikugawa, Japan MP-10.17 Validation of Novel ddPCR Bladder Cancer DNA Mutation Panels in Liquid BiopsiesAntara Karmakar, Australia
    Clinical
    |
    URO17™
    |
    docetaxel • GemRIS (gemcitabine-releasing intravesical system) • cretostimogene grenadenorepvec (CG0070)
    2ms
    ANBL19P1: Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date • Combination therapy
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    2ms
    Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma (clinicaltrials.gov)
    P3, N=60, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • thiotepa • Neupogen (filgrastim)
    2ms
    G-CSF After Chemo-radiation in Patients with Glioblastoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    temozolomide • Neupogen (filgrastim)
    2ms
    Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis. (PubMed, Ann Surg Oncol)
    This work describes the experience using T-VEC in melanoma at a single institution and highlights the presence of TERT promotor mutations as a possible driver of clinical response.
    Retrospective data • Journal • IO biomarker
    |
    TERT (Telomerase Reverse Transcriptase)
    |
    TERT mutation
    |
    Imlygic (talimogene laherparepvec)
    2ms
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    MYCN amplification • IL6 expression
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane
    2ms
    GM-CSF With Post-Transplant Cyclophosphamide (clinicaltrials.gov)
    P2, N=38, Recruiting, Northside Hospital, Inc. | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial primary completion date • Post-transplantation
    |
    cyclophosphamide • Leukine (sargramostim)
    2ms
    IMPALA-2: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Savara Inc. | Trial completion date: Jun 2025 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Nov 2023
    Trial completion date • Trial primary completion date
    3ms
    Brief Title: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC (clinicaltrials.gov)
    P2, N=50, Recruiting, CG Oncology, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cretostimogene grenadenorepvec (CG0070)
    3ms
    Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Amgen | Trial completion date: Aug 2038 --> Jan 2038 | Trial primary completion date: Aug 2038 --> Jan 2038
    Trial completion date • Trial primary completion date
    |
    Imlygic (talimogene laherparepvec)
    3ms
    Biomarker Assessments of Leukine During Treatment of Parkinson's Disease (clinicaltrials.gov)
    P1, N=7, Completed, University of Nebraska | Active, not recruiting --> Completed
    Trial completion
    |
    Leukine (sargramostim)
    3ms
    SESAD: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (clinicaltrials.gov)
    P2, N=42, Recruiting, University of Colorado, Denver | Trial completion date: Jul 2025 --> Oct 2026 | Trial primary completion date: Jul 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Leukine (sargramostim)
    3ms
    Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF (clinicaltrials.gov)
    P=N/A, N=100, Completed, Cairo University | Recruiting --> Completed | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Oct 2023 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Neupogen (filgrastim)
    3ms
    Keynote 935: Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (clinicaltrials.gov)
    P2, N=35, Completed, CG Oncology, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> May 2024
    Trial completion • Trial completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • cretostimogene grenadenorepvec (CG0070)
    3ms
    Continuous Versus Bolus Administration of G-CSF in Children With Cancer (clinicaltrials.gov)
    P4, N=20, Active, not recruiting, Chang Gung Memorial Hospital | Recruiting --> Active, not recruiting | N=40 --> 20
    Enrollment closed • Enrollment change
    |
    Granocyte (lenograstim) • Neupogen (filgrastim)
    3ms
    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=270, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    4ms
    Spatial Analysis of Tumor-Infiltrating Lymphocytes in mRCC Patients Treated with Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) and cemiplimab (REGN2810; Anti-PD-1) (EORTC-NCI-AACR 2024)
    AI-powered spatial analysis suggests that combination therapy with Pexa-vec and cemiplimab enhances the immune response, evidenced by increased TIL densities in the tumor microenvironment.Table 1: Changes in TIL Densities from Pre- to Post-TreatmentMeasureCohortPre-Treatment (mm²)(Median, IQR)Post-Treatment (mm²)(Median, IQR)p-value isTILOverall (n = 18)87.53 (179.37-114.65)214.02 (257.50-389.74)0.0040 Arm A (n = 9)41.30 (257.13-81.61)190.17 (830.30-389.34)0.0078 Arm B (n = 9)165.43 (180.52-147.69)390.17 (340.11-387.14)0.1641iTILOverall (n = 18)88.89 (129.08-116.99)161.11 (376.62-321.79)0.0237 Arm A (n = 9)56.42 (125.56-101.70)157.44 (421.03-469.55)0.0273 Arm B (n = 9)96.27 (57.33-132.29)154.92 (194.87-184.03)0.3716sTILOverall (n = 18)100.91 (291.38-193.61)219.37 (370.85-466.27)0.0599 Arm A (n = 9)35.59 (257.13-67.38)140.55 (286.46-157.15)0.0391 Arm B (n = 9)303.37 (171.24-319.84)353.58 (189.15-735.39)0.4961
    Clinical • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
    |
    CSF2 (Colony stimulating factor 2)
    |
    Lunit SCOPE IO
    |
    Libtayo (cemiplimab-rwlc) • Pexa-Vec (pexastimogene devacirepvec)
    4ms
    Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in NMIBC (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, CG Oncology, Inc.
    New P2 trial
    |
    cretostimogene grenadenorepvec (CG0070)